Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE 2: Phase III Tildrakizumab in Anti-TNF Naive Psoriatic Arthritis
jRCT2031210401Phase 3Completed
- Sponsor
- Sun Pharma
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Tildrakizumab with Placebo (2 arms). Primary endpoint: ACR20 response at Week 24. Started Feb 2022; status: completed.
02
Drugs
tildrakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT2031210401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210401.